Table 2. Characteristics of eligible studies for clinicopathological features in meta-analysis.

Author	Year	country	Age/ Median (range)	N	Positive (%)	Location	Cut-off	T	N	M	S	G	ER	PR	NOS
Talvensaari-Mattila,A.	1998	Finland	55(NR)	169	84.00	T	≥1%				√				8
Jones,J.L.	1999	England	NR	104	36.60	T/S	≥1%		√				√	√	7
Fan,S.Q.	2003	China	53.5(26–68)	66	71.20	T	CS	√	√		√		√	√	8
Nakopoulou,L(1).	2003	Netherlands	57.31(25–87)	135	75.60	T	≥10%	√	√		√	√	√		7
Nakopoulou,L(2).	2003	Netherlands	57.31(25–87)	135	27.40	S	≥10%	√	√		√	√			7
Talvensaari-Mattila,A.	2003	Finland	52(26–85)	453	78.10	T	≥1%	√	√	√		√			8
Hirvonen,R.	2003	Finland	NR(26–85)	137	83.20	T	≥1%	√			√		√	√	6
Li,H.C.	2004	China	NR	270	56.70	T	≥1%	√				√	√	√	8
Zhou,S.	2005	China	58(41–69)	112	53.60	T/S	≥5%	√	√		√	√	√	√	7
Zhang,Y.G(1).	2007	China	54.7(30–78)	92	19.60	T	≥30%	√	√		√	√	√	√	9
Zhang,Y.G(2).	2007	China	54.7(30–78)	92	55.40	S	≥30%	√	√		√	√	√	√	9
Sullu,Y.	2011	Germany	52(22–85)	140	92.90	T	CS	√	√	√		√	√	√	8
Niemiec,J.A.	2012	United States	60(37–88)	146	9.60	S	≥1%					√	√	√	9

NR not reported, T Tumor cells, S stromal cells, T/S either tumor cells or stromal cells, CS complex score combining intensity and percentage, √ data available for calculating OR and 95%CI.